Screening for Early Biomarkers of Cisplatin-Induced Acute Kidney Injury in Rats Through Serum Metabolomics Technology

Jinru Yang,Mingkang Zhang,Fenglin Ran,Xueyan Gou,Yanrong Ma,Xinan Wu
DOI: https://doi.org/10.29271/jcpsp.2024.08.936
Abstract:Objective: To systematically identify early biomarkers of cisplatin-induced acute kidney injury (AKI) in rats. Study design: An experimental study. Place and Duration of the Study: Experimental Animal Laboratory of Lanzhou University, Gansu, China, and the Department of Pharmacy, The First Hospital of Lanzhou University, Gansu, China, from July 2022 to October 2023. Methodology: In this study, an AKI model was established by continuously injecting cisplatin into rats at a dose of 1 mg/kg once a day for control group and for 2, 3, 4, and 5 days to other four groups, respectively. Subsequently, rat plasma samples were collected for metabolomics analysis to identify early differentiated metabolites in the plasma prior to creatinine elevation. Furthermore, accurate HPLC-MS/MS methods were developed to validate the biomarker variation in other AKI models. Results: The occurrence of time-dependent renal cortical injury and significant alterations of creatinine (Cr) concentration were observed on day-4 and 5, which demonstrated successful model construction. Sixty-six compounds changed on Day-2 while 61 compounds changed on Day-3. Eleven compounds with variable importance in projection (VIP) >1.5 and false discover rate (FDR) <0.2 were selected and identified by HPLC-MS/MS. Among these, N-acetylglutamine and citramalic acid changed earlier than serum creatinine (sCr) in the AKI model. Conclusion: N-acetylglutamine and citramalic acid may serve as early biomarker of cisplatin-induced AKI. Key words: Acute kidney injury, Biomarker, Cisplatin, Metabolomics, LC-MS/MS, Rats.
What problem does this paper attempt to address?